Most graft-versus-host disease (GHVD) prophylaxis regimens utilized during allogeneic hematopoietic stem cell transplantation (HSCT) contain either cyclosporine (CSA) or tacrolimus alone or in combination with other agents. An allergic reaction to either of these agents is extremely rare, possibly due to the immunosuppression induced by the conditioning regimen. In the event of a reaction involving both agents, however, the optimal choice of GVHD prophylaxis is unclear.
A 7-year-old boy of Chinese descent with an on-therapy bone marrow relapse of B-precursor acute lymphoblastic leukemia was admitted for allogeneic HSCT from his human lymphocyte antigen-identical sister. He had a prior history of multiple food allergies, including reactions to nuts and sesame. His conditioning regimen consisted of total body irradiation delivered over 4 days in 11 fractions of 120 cGy each (total dose 1320 cGy), followed by one dose of intravenous etoposide (60 mg/kg over 4 h). 1 He was initially ordered to receive intravenous CSA (5 mg/kg) given over 20 h starting on Day À2, then tapered per institutional protocol, followed by methotrexate (15 mg/m 2 on Days þ 1, 10 mg/m 2 on Day þ 3, þ 6 and þ 11) for his GHVD prophylaxis regimen. 2 Within minutes of starting CSA, he developed angioedema of the lips and respiratory distress. The infusion was halted and he received diphenhydramine and hydrocortisone (HC), with resolution of his symptoms. The following day, his GVHD prophylaxis was switched to intravenous tacrolimus (0.03 mg/kg) given over 24 h. 2 Approximately 12 h into the infusion, he developed generalized urticaria. Again, the infusion was halted, and he was treated with diphenhydramine and HC, with resolution of his symptoms. After 12 h, he was premedicated with diphenhydramine and HC, and the tacrolimus restarted. Once again, urticaria developed. Having established that the patient was having severe allergic reactions to both intravenous CSA and tacrolimus, we were forced to switch either to an alternate route of delivery or to another immunosuppressive medication. Owing to his mucositis, we were concerned that the patient would have poor or erratic absorption of oral tacrolimus or oral CSA; therefore, we decided to utilize intravenous mycophenolate mofetil (MMF), starting at a dose of 15 mg/ kg/dose every 12 h. 3 Owing to undetectable levels of mycophenolate acid (MPA, Mayo Labs, Rochester, MN, USA), his dosing interval was escalated first to every 8 h, then his total dose was increased to 600 mg/m 2 and finally, 900 mg/m 2 , which ultimately resulted in a level of 0.9 mg/ ml 3 . He received a total of 6.4 Â 10 6 CD34 þ bone marrow cells/kg from his sister. His immediate post transplant phase was complicated only by grade II mucositis. He had neutrophil engraftment (ANC4500/ml for 2 consecutive days) on Day þ 24. Owing to severe nasal hemorrhages, his platelet counts were kept greater than 35 000 with his last platelet transfusion on Day þ 32. On Day þ 24, his mucositis had significantly resolved and he was switched to oral tacrolimus, which he tolerated without any allergic reaction. He was discharged on Day þ 30. Analysis of variable nucleotide tandem repeats (VNTRs) on Day þ 23 showed 100% of blood CD3 þ cells and 95% of marrow CD34 þ cells were of donor origin. He is now Day þ 118 and has no evidence of acute GVHD. His VNTRs continue to show 98-100% donor engraftment.
Anaphylaxis to intravenous CSA is a rare event during HSCT. [4] [5] [6] Intravenous cyclosporine (Bedford Laboratories, Bedford, OH, USA) contains polyoxyethylated castor oil as a solubilizer, as do the Neoral formulations (Novartis Pharmaceuticals, East Hanover, NJ, USA) but not the oral Sandimmune formulations (Novartis Pharmaceuticals, East Hanover, NJ, USA). Previous reports have implicated castor oil as the likely causative agent of anaphylactic reactions. 5, 6 In a patient with anaphylaxis to CSA after heart transplantation, hypersensitivity testing revealed a positive intradermal reaction and basophil activation to Cremophor EL (polyethoxylated castor oil; BASF, Berlin, Germany). 7 Anaphylaxis to tacrolimus during HSCT has only been reported once before, in a patient also allergic to CSA. 4 As intravenous (but not oral) tacrolimus also utilizes a polyoxyl-hydrogenated castor oil as a solubilizer (Astellas Pharma, Deerfield, IL, USA), Takamatsu et al. 4 suggested that the castor oil was the likely triggering agent, rather than a dual allergy to both CSA and tacrolimus. They switched their patient to oral Sandimmune CSA with good tolerance and only grade I acute GVHD. 4 Similarly, we felt that the allergic reactions in our patient were likely in response to the castor oil solubilizer, and when we eventually switched our patient to oral tacrolimus, he had no reaction.
Given in conjunction with either CSA or tacrolimus, MMF has been used to replace post transplant methotrexate in several recent studies. 3, [8] [9] [10] MMF does not use castor oil in either its intravenous or oral formulations (Roche Pharmaceuticals, Nutley, NJ, USA). However, the optimal dose and timing of MMF in the pediatric population is unclear. Several different methods have been used to monitor for efficacy and toxicity of MMF during HSCT, including the determination of trough MPA levels, 3 MPA concentration steady state levels 9 and MPA area under the curve. 10 Fortunately, our patient tolerated MMF administration extremely well, with no significant delay in neutrophil or platelet engraftment, no specific gastrointestinal symptoms and no GVHD.
In conclusion, anaphylactic reactions to castor oil, while rare during HSCT, can be problematic owing to its usage as a solubilizer in the intravenous preparations of both CSA and tacrolimus, the two mainstays of GVHD prophylaxis therapy. Clinicians faced with this problem may consider utilization of intravenous MMF, which is free of castor oil and has been shown in clinical trials to be effective in preventing GVHD. Further trials to determine the optimal dose and timing of MMF in the pediatric population, however, are indicated. 
